INTRODUCTION
Peripheral arterial disease (PAD) is a major manifestation of arteriosclerosis, [1] [2] [3] and affects approximately 20% of adults older than 55 years and an estimated 27 million patients in North America and Europe. 4, 5 The primary risk for PAD patients is ischemic cardiovascular events including non-fatal ischemic stroke, myocardial infarction (MI) and cardiovascular death, as well as coronary, carotid and lower extremity revascularization procedures and major amputation. 6 Major amputation is usually required in more than one-third of the critical limb ischemia (CLI) patients. The 1-and 2-year mortality rate in patients with CLI is 20% (refs 7, 8) and 32% (refs 9, 10) respectively, and for all patients with PAD, the 3 year mortality has been reported to be as high as 23%. 9 Primary therapy for PAD patients targets the generalized atherosclerotic process, including aggressive risk factor modification and anti-platelet therapy. 7 Angiogenesis via gene therapy is a novel strategy that is designed to increase the blood perfusion in ischemic tissues. 10, 11 In particular, beneficial effects have been demonstrated using gene transfer of fibroblast growth factor-1 (FGF-1) leading to a significant decrease in the major amputation rate in the FGF-1-treated patients. 12 Although short-term studies have demonstrated excellent safety, the long-term safety of this approach is unknown. Concerns remain that gene therapy may lead to pathological angiogenesis, including increased rates of cancer, retinopathy or an increase in acute coronary syndromes that may be induced by plaque neovascularization. 11 We report the long-term (43 years) follow-up results of PAD patients enrolled in the non-controlled phase I trials PM 101 and 105, and in the randomized placebo-controlled phase II trials PM 201, PM 202 and PM 211 treated at four centers that included their patients in a long-term PAD outcomes registry called OPTIMIST (US database) and EuroOPTMIST (European database). This registry included 93 patients (33.3%) of the total studied population of those five trials (n¼279; Table 1 : Study names and patient numbers). Only the four centers with the highest patient populations in these five non-viral fibroblast growth factor 1 (NV1FGF) trials participated in the longterm follow-up to ensure optimal data quality. Tables 2a and b : Safety and efficacy of NV1FGF versus placebo in CLI patients (2a) and in intermittent claudication (IC) patients at 3 years (2b).
RESULTS

An overview of safety results is presented in
Deaths
None of the patients were lost to follow-up. Death occurred only in the CLI group. The causes of death for the 16 patients treated with NV1FGF were stroke (four cases), cardiovascular death (two cases), chronic heart failure, lung cancer, intracerebral hemorrhage, pneumonia and kidney failure (one case, each). Five patients died from unknown reason. The causes of death in the nine patients who received placebo were acute MI, stroke in one case, cardiovascular death in one case, chronic heart failure in one case, sudden cardiac death in one case, pneumonia in two cases, multiorgan system failure in one case and one patient died from unknown reason. Time to death in patients suffering from CLI is shown in Figure 1 .
Cardiovascular events
Rates of cardiovascular events in patients before and after inclusion into the trials at 1, 2 and 3 years are presented in Table 3 : Cardiovascular events during the time periods 3 years before and 3 years after gene therapy.
Cancer
There were three patients who had a history of carcinoma at baseline. Of these, two patients had basal cell carcinoma of the skin, which had been excised and removed, and one patient had a history of prostate cancer for more than 6 years before study entry. Only two patients developed a new cancer, both treated with NV1FGF. This included a patient who developed a new lung cancer at 9 months and a patient diagnosed with colon cancer at 19 months after treatment with NV1FGF. I  2  2  PM 105  I  13  13   Talisman 201  II  22  20  42  PM 202  II  10  5  15   IC  Talisman 211  II  11  10  21 Abbreviations: CLI, critical limb ischemia; IC, intermittent claudication; NV1FGF, non-viral fibroblast growth factor-1. Long-term safety of NV1FGF gene therapy A Niebuhr et al
Retinopathy and renal dysfunction
There were two new cases of retinopathy reported at 36 months, one in each treatment group. None of the patients suffering from renal dysfunction showed deterioration of kidney function at 3 years. Creatinine values ranked in these patients between 1.6 and 2.4 mg dl À1 at baseline and between 1.6 and 2.5 mg dl À1 at 3 years.
Amputation
Major amputation was performed in seven NV1FGF-and seven placebo-treated patients with CLI (P¼0.758; Table 4 : Amputation rate in CLI patients randomized to PM 201 or PM 202). Time to major amputation is shown in Figure 2 .
Combined end point: major amputation and death
The combined end point of death or major amputation occurred only in the CLI group (Table 4 : Amputation rate in CLI patients randomized to PM 201 or PM 202). Time to major amputation combined with death in patients suffering from CLI randomized to PM 201 und PM 202 is shown in Figure 3 .
DISCUSSION
This four-center PAD registry allows for the first report on long-term follow-up of patients who had received angiogenic gene therapy. It was designed to explore the effects of angiogenesis gene therapy administered at various doses and regimens predominantly on long-term safety. It reports the 3-year follow-up of 93 patients recruited in four centers in the Europe and the United States for the phase II trials PM 201 and PM 211, Aventis NV1FGF PM 202, and the phase I trials PM 101 and 105. Only the four centers with the highest patient populations participated in this non-funded long-term follow-up to ensure best possible data quality. All patients, placebo or NV1FGF from these centers who had participated in these five NV1FGF trials were included. No patient was lost to follow-up from this patient population.
Deaths
Consistent with the recognized high mortality associated with PAD, 25 patients (all with CLI) died during the follow-up period of 3 years. In several studies, the mortality at 1 year in CLI patients is approximately 20% (refs 7, 13) , and in our study, eight NV1FGF patients (17%) and five placebo patients (20%) died within 1 year. At 2 years, an additional five NV1FGF patients (27.7% of total) and three placebo patients (32% of total) had died consistent with the published data of 32% mortality at 2 years in CLI patients. 8 In year 3, an additional three NV1FGF patients and one placebo patient died for a total of 34% and 36% respectively. None of the patients of the IC group died in the follow-up period. Therefore, the total 3 year mortality rate was 27.6% after NV1FGF versus 25.7% after placebo. Brevetti et al. show a death rate of 4.9-23.3% of patients suffering from PAD in a follow-up of 32 months. 14 Thus, there were similar survival rates at 1, 2 or 3 years in this relatively small patient group, including 58 patients who received NV1FGF compared with those reported in the literature.
Only three of the patients of the NV1FGF group (6.4%) and four patients of the placebo group (16%) died from acute MI, chronic heart failure or sudden cardiac death. A rate between 2.4 and 55% of patients with PAD who died from complications related to coronary artery disease is found in literature. 1, 15 Furthermore, four patients (8%) of the NV1FGF group and one patient (4%) of the placebo group died from stroke. Published rates of stroke mortality in this population are approximately 7-10% in patients with CLI. 12, 14, 15 Finally, nine patients (19.2%) of the NV1FGF group and three patients (12%) of the placebo group died from non-vascular causes, such as pneumonia, kidney failure and intracerebral hemorrhage, or for unknown reasons. The non-vascular death rate has approximated 25-30% in published literature in patients with CLI. 14, 15 In summary, the rates and causes of death in patients with PAD treated by either NV1FGF or placebo was comparable with reported values.
Cardiovascular events
All patient groups in this PAD registry had a high prevalence of cardiovascular events, such as strokes and MI, before study enrollment. Thus, cardiovascular events during follow-up were less frequent compared with those 3 years before randomization, especially in the Long-term safety of NV1FGF gene therapy A Niebuhr et al CLI group (Table 3 : Cardiovascular events during the time periods 3 years before and 3 years after gene therapy). One possible explanation is that all patients were on optimal medication to control risk factors and cardiovascular disease as they remained under supervision by their vascular specialists. 7 Of all patients, 70% suffered from coronary artery disease. Previous studies have shown that 10-66% of patients with PAD also suffer from coronary artery disease [16] [17] [18] and 5-41% or more have cerebrovascular disease. [19] [20] [21] The Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori (I.C.A.I. group) 9 demonstrated a 29.1% cardiovascular event rate (including 18.8% MIs and 10.3% strokes in the 2 years follow-up) of patients with CLI. Schiano et al. 22 reported in a 2-years follow-up of 60 patients with IC with a 8.3% cardiovascular ischemic event rate, including 3.3% MIs and 5% strokes.
Interestingly, this PAD registry reveals a rather low rate of cardiovascular events at 3 years follow-up compared with the period of time before inclusion into one of the gene therapy trials.
Cancer
Two cases of newly diagnosed cancer (one lung cancer, one colon carcinoma) occurred in the NV1FGF group. FGF may contribute to the pathogenesis of cancer 23 by promoting cell cycle progression and inhibiting pathways of cell death. 24 Several FGFs were initially cloned from human and animal tumors. Future work will be required to determine whether FGF activation by itself may cause primary human tumors or whether it is a progression factor in the pathogenesis of cancer. In addition, the question arises, whether local, intramuscular gene application might promote the same oncogenic risk, whether the protein is expressed only locally, as has been hypothesized for systemic administration. Initial studies focused on the regulation of cell proliferation, migration and differentiation, whereas more recent work has addressed the negative effect of FGFs and FGF receptors on the proliferation of some cell types, which was surprising, as FGFs were thought to always promote proliferation. 23 Lung cancer and colon carcinoma are known to be the most common fatal cancers. Their incidence ranges from 40.3 to 137.9 per 100 000 for lung cancer and from 51.9 to 71.7 per 100 000 for colon carcinoma. The broad estimated prevalence range for each cancer reflects the difference in the prevalence of risk factors as smoking in the different parts of the United States. 25 Both patients in this 3-year follow-up who suffered from cancer were smokers and had other risk factors as arterial hypertension, hypercholesterolemia and high body mass index. A correlation between risk factors for coronary artery disease as arterial hypertension, hypercholesterolemia, cigarette smoking and obesity is known. 26, 27 The patient who experienced the newly diagnosed lung carcinoma was a current smoker with at least 20 pack years. Smoking is associated with increased risk of lung cancer and colon carcinoma. 28 The incidence of lung cancer in men aged 50-71 years is 1.5%, whereas the incidence of current smokers is much higher with 12.6%. 29 On the other hand, with the small number of patients, a role of NV1FGF cannot totally be excluded.
It may be noteworthy that in the five clinical studies, and among the entire studied population of 279 patients included in NV1FGF studies (NV1FGF n¼192 and placebo n¼87), the incidence of cancers including unspecified neoplasms was 4.6% (4/87) in the placebotreated patients and 5.2% (10/192 ) in the NV1FGF-treated patients at the end point at 6 or 12 months (mean follow-up 10 months). In addition, the incidence of new cases of lung cancer was 3/87 in the placebo-treated patients versus 1/192 in the NV1FGF-treated patients supporting the notion that intramuscular NV1FGF may not be associated with an increased risk of cancer in this short period of observation. Furthermore, in the phase III TAMARIS trial there were 1.6% (4/259) malignant neoplasms in the placebo-treated group versus 2.6% (7/266) in the NV1FGF-treated group at 12 month. 30 Those numbers may not rule out a role of NV1FGF in cancer development totally at long-term, although, make it less likely.
Retinopathy
Both patients with newly diagnosed retinopathies were suffering from diabetes mellitus, arterial hypertension and hypercholesteremia. Retinopathy is known to occur with increased frequency in individuals with hypertension and diabetes, obesity and metabolic disorders. 31 Overall, only two cases of newly diagnosed retinopathy out of 154 patients had been reported in TALISMAN 201 and TALISMAN 211 trials together at 12 or 6 months 12 and none in the phase I study with patients suffering from CLI.
Renal dysfunction
There occurred no new case of renal dysfunction as those which existed before gene therapy. In previous studies using NV1FGF, no side effects concerning renal failure were reported. 30 Amputation All major amputations occurred within 1 year after randomization. It appears that the early efficacy in FGF1 gene therapy in major amputation is lost at later times. This may be because of a more shortterm effect, which is not apparent at later time points. An amputation rate of 13.8% at 2 years has been reported in patients with CLI, 14 which is little lower than the rate reported in this PAD registry over 3 years (21.9% versus 28%, NV1FGF versus placebo). Amputation risk always remains high in the index leg despite study enrollment (8.75% in the NF1FGF group versus 71.4% in the placebo group). A more homogenous and larger patient population and a double-blind randomized study design would be necessary to evaluate amputation as an efficacy end point, as the decision to amputate remains variable and dependent on the patient's limb risk, their general morbidity, and other factors. 6 This long-term follow-up is ongoing and will be extended to at least 10 years follow-up. This registry was clearly established to evaluate the primarily long-term safety of gene therapy. Here patients followed entered at different stages of PAD and planned amputation and received a different dose and regimen ranging from a single administration of 0.5 mg to 4Â4 mg (that is, total dose 16 mg) for the CLI group and 4Â8 mg (that is, total dose 32 mg) for the IC group. Thus, the observational design of the registry, the open label assessment and the small patient numbers available in each group, including the CLI group, do not allow for an evaluation of efficacy.
In this PAD registry, no patient with IC underwent amputation in the follow-up period. Recent published data corroborate the finding that limb loss is a rare event in patients with IC with a 5-year risk of major amputation of only 2%. 15 Major amputation and death Considering combined end points for major amputation and death this registry demonstrates a rate of 31.3% in the NV1FGF group and 32% in the placebo group at 3 years (P¼0.540; Figure 3 : time to major amputation combined with death in patients suffering from CLI randomized to PM 201 and PM 202). In comparison, Criqui et al. 5 showed a higher mortality among amputees than in non-amputees (52.8% versus 29.8%). Thus, there was a trend that participating in these clinical studies reduced the risk for major amputation and death, particularly, in the NV1FGF group of patients randomized to one of the phase II trials.
Revascularization procedures
Surgical revascularization and percutaneous transluminal intervention are appropriate therapy options for patients with CLI to prevent limb loss and invalidization. 7 This PAD registry demonstrates a low rate of revascularization procedures in all patient groups. There was a trend toward less frequent revascularization procedures in the placebo group. However, this can be attributed to the fact that all and major amputations were more frequent because of aggravation of disease in the same group with less limbs left for potential revascularization procedures.
MATERIALS AND METHODS
Study design
To collect long-term safety and efficacy data, this registry was instituted to allow for prospective long-term follow-up of gene therapy patients using the same database in one United States and three European centers (Germany, France and Switzerland). Approval was obtained by the local Ethics Committees at individual institutions.
The results are based on the long-term follow-up of 93 patients enrolled in two phase I studies (Aventis PM 101 and PM 105; Europe and US) 31 and three phase II studies (TALISMAN PM 201 (Europe) and PM 211 (Europe) and Aventis NV1FGF PM 202 (US); 12 Table 1 : Study names and patient numbers).
Depending on their objectives and phase, these five studies had a noncontrolled (n¼2) or placebo-controlled design (n¼3), included patients with IC (n¼21), CLI with skin lesions (Fontaine IV; n¼70), and patients with a planned amputation (n¼2). Depending on the study, patients treated with NV1FGF who received a dose and regimen ranging from a single administration of 0.5 mg to a four administrations at 2-week intervals of 4 mg were included in this study, resulting in a total dose of 32 mg (Table 5 : Patients of various study groups and disease stages included to different treatment groups and intended dosages).
Patient population
Overall, 93 patients of the total 280 studied patients included in these five studies were included at these four centers alone representing the centers with highest patient numbers recruited into NV1FGF trials and willing to participate in this registry. Patients were exposed to NV1FGF (n¼58) or placebo (n¼35) within five different angiogenic gene therapy trials PM 101 (n¼13), PM 105 (n¼2), PM 201 (n¼42) PM 202 (n¼15) and PM 211 (n¼21).
PM 101 (total number of patients n¼51) was a phase I, non-controlled, open-label, dose-escalation trial in patients with CLI to assess safety and tolerability of NV1FGF in patients with CLI (Fontaine III and IV). The study demonstrated a reduction in pain and ulcer size as well as an increase in transcutaneous oxygen pressure 11, 15 with excellent safety up to a dose of 16 mg. PM 105 (total number of patients n¼6) was a non-controlled phase I trial in patients with CLI before planned amputation to determine local NV1FGF expression in injected muscle assessed at 3 to 5 days after the planned amputation.
Results demonstrated that human myofibers express NV1FGF mRNA and FGF1 protein following 0.5-4 mg of NV1FGF intramuscular administration. The FGF1 expression is limited to the injections sites and was not detected in muscle distant from the injection sites nor in the circulation. 16 TALISMAN PM 201 (n¼118) was a phase II, double-blind, placebo-controlled, multicenter, safety and efficacy trials comparing intramuscular injections of four times 4 mg of NV1FGF versus placebo in patients with CLI and at least one non-healing ulcer and no option for revascularization in Europe. 11, 14 TALISMAN PM 201 demonstrated a significant reduction in all amputations and 55% risk reduction of major amputations as well as a delay in time to major amputation or death in CLI patients. 14 There was no difference in ulcer healing, probably because of the severity of the baseline lesions. 12 PM 202 was a phase II, doubleblind, placebo-controlled, dose finding study assessing the effect of several doses and regimens of NV1FGF versus placebo on transcutaneous oxygen pressure. 32 Patients were presenting with CLI and at least one non-healing ulcer and no option for revascularization were randomized in six arms: placebo (n¼16) and five NV1FGF arms (4Â0.5 mg (n¼11), 4Â2 mg (n¼11), 4Â4 mg (n¼11), 2Â8 mg (n¼11)). The study was performed only in the United States, and demonstrated an improvement in ulcer healing but no difference in the primary end point of transcutaneous oxygen pressure that was associated with a high variability. 11 Finally, TALISMAN PM 211 (n¼34) was a phase II, doubleblind, placebo-controlled trial in patients with claudication assessing the safety of two doses of NV1FGF (16 mg and 32 mg) versus placebo in patients with intermittent claudication. The Data Monitoring Committee concluded on the absence of a safety issue for both doses in this study population. This data base was designed to evaluate the long-term follow-up on amputation rate, death rate and safety. Those end points were simular to those in the study protocols used for the five NV1FGF trials.
In the registry, the average age of patients as well as other baseline characteristics, such as previous MI, stroke, diabetes mellitus or smoking in the patient populations, were relatively balanced comparing the two groups of the different stages (Table 6 : Patient demographics and disease status at baseline in CLI patients and IC patients). The total dose patients received in each trial is outlined in Table 5 : Patients of various study groups and disease stages included to different treatment groups and intended dosages).
As amputation was planned only few days after receiving NV1FGF in patients included the PM 105 and PM 101 studies, only patients randomized to the phase II studies PM 201 and PM 202 (n¼53, 30 versus 23, NV1FGF versus placebo) were considered for the evaluation of amputation.
Follow-up evaluation
Prospective follow-up evaluations took place 12, 24 and 36 months after inclusion in one of the five trials, and included the parameters specified in Tables 2a and b : Safety and efficacy of NV1FGF versus placebo in CLI patients (2a) and IC patients (2b).
Patients were seen regularly in the outpatient clinic whenever possible or patients and/or their physicians had to be interviewed at set time points. In the double-blind placebo-controlled studies, the assessment was blind only during the initial study phase. Long-term follow-up within the registry was open label.
Statistical analysis
Results are presented descriptively by reporting location and scale statistics (mean and standard deviation) as well as rates of target events. Point estimates are supplemented by 95% confidence intervals. Inductive statistical analyses were performed by means of significance tests. For comparison of means between independent or paired patient groups, the nonparametric MannWhitney U-test or Wilcoxon's signed rank test were applied, respectively. Rates of target events were compared by means of the Fisher's exact test. Time-toevent data were evaluated by survival analytic methods, that is, Kaplan-Meier estimation of survival curves and comparison of different survival distributions by means of the Log-rank test.
All statistical analyses are intended to be explorative and not confirmative. P-values are regarded significant when Po0.05. No adjustment for multiple testing was carried out. Statistical analyses were performed using SPSS (version 15.0.1G for Windows, SPSS Inc., Chicago, IL, USA). Long-term safety of NV1FGF gene therapy A Niebuhr et al
CONCLUSION
OPTIMIST and EuroOPTIMIST registries led to the following main outcome in 93 evaluable patients at 3 years: NV1FGF therapy appears to be safe for a period of at least 3 years after administration, and specifically was not associated with a detectable increased risk for cancer, retinopathy, renal dysfunction or death. As anticipated, given the registry design and low number of patients followed-up, no difference in the number of all and major amputations was observed in patients with CLI exposed to various doses of NV1FGF compared with placebo. The patient population divided into several subgroups was far too small to evaluate efficacy. The major contribution from this four center registry should be limited to an early evaluation of safety only. Data suggest that there is no overt adverse long-term safety signal in the studies to date of NV1FGF angiogenesis gene transfer. At 3 years, NV1FGF did not induce detectable disease in tissues other than the skeletal muscle target, nor did it increase the risk of retinopathy, cancer or death in patients with PAD. Interestingly, cardiovascular events (for example, non-fatal MIs) were less frequent in both treatment groups within 3 years before inclusion into those trials compared with the 3-year interval following study inclusion. Overall, conclusions are limited by the size of patient group, which consisted only of 93 patients, on the other hand, hardly any long-term data following angiogenesis gene therapy have become available to date.
Further trials such as the actual phase III Therapeutic Angiogenesis for the Management of Arteriopathy in a double blind Randomized International Study initiated to assess worldwide in 525 CLI patients with skin lesions, unsuitable for revascularization the efficacy of NV1FGF versus placebo with the combined primary end point of amputation or death will allow for further insights into efficacy and safety of NV1FGF gene transfer. 31 Patients included in this phase III trial will also be followed at long-term within a registry. However, until these data will become available it will take several more years. Long-term safety of NV1FGF gene therapy A Niebuhr et al
